$ZLCS News Zalicus to discontinue rheumatoid art
Post# of 144498
Zalicus to discontinue rheumatoid arthritis drug 10:38 a.m. Sept. 10, 2012 - MarketWatch.com
Pfizer, Affymetrix weigh on drug stocks 2:04 p.m. July 7, 2011 - Val Brickates Kennedy
Tuesday’s biggest advancing and declining stocks 2:35 p.m. July 5, 2011 - Kate Gibson
Drug stocks sluggish; Zalicus jumps 12:17 p.m. July 5, 2011 - Val Brickates Kennedy
Zalicus jumps 10% on stock rating 9:18 a.m. July 5, 2011 - Val Brickates Kennedy
5 reasons I can’t sell B. of A. — should you buy? 8:42 a.m. April 21, 2011 - Jeff Reeves
10 expert stock picks for 2011 12:02 a.m. Jan. 5, 2011 - Jeff Reeves
Zalicus trades sharply higher on heavy volume 1:28 p.m. Nov. 26, 2013 - Seeking Alpha
Zalicus: Where From Here? 12:02 p.m. Nov. 15, 2013 - Seeking Alpha
UPDATE: Oppenheimer Downgraded Zalicus 2:49 p.m. Nov. 11, 2013 - benzinga.com
Intel Buys ‘Kno’ to Reinforce Education Laptops Sideline and 2 Other Hot Stocks to Watch 11:35 a.m. Nov. 11, 2013 - Wall St. Cheat Sheet
Zalicus' Z160 Fails, What Now? 11:05 a.m. Nov. 11, 2013 - Seeking Alpha
Zalicus: Investors Get Sucker Punched 10:58 a.m. Nov. 11, 2013 - Seeking Alpha
UPDATE: Zalicus Reports Results from Phase 2 Clinical Trials of Z160 in Chronic Neuropathic Pain 7:32 a.m. Nov. 11, 2013 - benzinga.com
Key Issues Surrounding The Zalicus Catalyst Trade 8:56 a.m. Nov. 8, 2013 - Seeking Alpha
Clues And Controversy: Why Zalicus Shares Could Be Set For A Rally 9:08 a.m. Nov. 6, 2013 - Seeking Alpha
Where Is Zalicus After Trial Results? 2:06 p.m. Nov. 5, 2013 - Seeking Alpha
Recent FDA News Makes A Zalicus Trade Look Even More Compelling 4:27 a.m. Oct. 29, 2013 - Seeking Alpha
Zalicus: An Upcoming Catalyst With Huge Potential 10:06 a.m. Oct. 24, 2013 - Seeking Alpha
4 Biotechnology Stocks With Room To Climb 8:10 a.m. Oct. 15, 2013 - Seeking Alpha
A High Risk-High Reward Biopharma With Two Pending Catalysts 7:16 a.m. Oct. 4, 2013 - Seeking Alpha
Zalicus Shares Nosedive Following News of 1-for-6 Reverse Split 2:57 p.m. Oct. 2, 2013 - benzinga.com
Zalicus Is A Promising Biotech With Echoes Of Acadia Pharmaceuticals 9:25 a.m. Sept. 20, 2013 - Seeking Alpha
AcelRx Pharmaceuticals To Submit NDA By End Of September, May Be Acquired Soon 6:55 a.m. Sept. 20, 2013 - Seeking Alpha
10-Q: ZALICUS INC. 3:11 p.m. Aug. 5, 2013 - Edgar Online - (EDG = 10Q, 10K)
For Zalicus, Z160 Data In October Could Be Huge 11:22 a.m. Aug. 1, 2013 - Seeking Alpha
Zalicus Announces Advancing Clinical Development of Z944 5:38 a.m. June 4, 2013 - benzinga.com
Healthcare Companies Report Appointments, Phase 1 Studies, and Corporate Growth - Research Report on HCA, Isis Pharmaceuticals, Oxygen Biotherapeutics, Insmed, and Zalicus 8:00 a.m. Dec. 3, 2013 - PR Newswire
ELTK, AAPL, ZLCS and AGNC added to NASDAQ Active Stock Watch List at EPR 10:06 a.m. Nov. 27, 2013 - ACCESSWIRE
Bullish Stocks Analysis: Zalicus Inc, Camtek Ltd, JPMorgan Chase & Co, Nevada Gold Corp 9:02 a.m. Nov. 27, 2013 - ACCESSWIRE
Bearish Stocks Trend Analysis: Green Mountain Coffee Roasters, Zalicus Inc, Time Warner Cable, Baidu, Qihoo 360 Technology 8:47 a.m. Nov. 27, 2013 - PR Newswire
Presentations and Quarterly Reports - Research Report on NPS, Zalicus, Charles River, Insulet, and Sagent 8:00 a.m. Nov. 14, 2013 - PR Newswire
TrendingWallStreet.com Initiates Trend Research on TRMR, ENIP, STPFQ, and ZLCS 12:23 a.m. Nov. 13, 2013 - ACCESSWIRE
FDA Updates, Corporate Developments: Viropharma, 3D Systems Corporation, Cirrus Logic, Zalicus, The Boeing Company 8:53 a.m. Nov. 12, 2013 - PR Newswire
TrendingWallStreet.com Initiates Volume Research on TRMR, ENIP, STPFQ, and ZLCS 1:06 a.m. Nov. 12, 2013 - ACCESSWIRE
ZLCS, CLRX, DSCO and GALE added to NASDAQ Active Stock Watch List at GSR 10:20 a.m. Nov. 11, 2013 - ACCESSWIRE
Zalicus Reports Results from Phase 2 Clinical Trials of Z160 in Chronic Neuropathic Pain 8:30 a.m. Nov. 11, 2013 - BusinessWire
Closing of Over-Allotment Options, Receiving Orphan Drug Designations, Release of Clinical Data, and Obtaining Important Patents - Research Report on Galena, Zalicus, Infinity, Stemline and Insmed 8:00 a.m. Nov. 5, 2013 - PR Newswire
Zalicus Reports Financial Results for the Third Quarter 2013 7:30 a.m. Nov. 4, 2013 - BusinessWire
Zalicus Announces Positive Results of Z944 Phase 1b Clinical Study in Pain 7:30 a.m. Nov. 1, 2013 - BusinessWire
Under The Radar Big Pharma Partnership Opportunity for Zalicus,Targacept and ACADIA 4:17 a.m. Oct. 31, 2013 - ACCESSWIRE
Healthcare Companies Report Quarterly Financial Results - Research Report on Celgene, Natus, Merit Medical, Invacare, and Zalicus 8:00 a.m. Oct. 30, 2013 - PR Newswire
Zalicus Regains Compliance with Nasdaq Listing Requirements 6:30 a.m. Oct. 15, 2013 - BusinessWire
Zalicus Announces 1-for-6 Reverse Stock Split 3:01 p.m. Oct. 2, 2013 - BusinessWire
Presentation on Research Findings, Recognitions, Clinical Trial Results, and Orphan Drug Designations - Research Report on Celgene, Biogen Idec, Amgen, Nektar, and Zalicus 7:00 a.m. Oct. 2, 2013 - PR Newswire
TSLA, AGNC, GERN and ZLCS added to Nasdaq Active Stock Watch List at GSR 8:05 a.m. Oct. 1, 2013 - ACCESSWIRE
Zalicus' Z160 Receives Orphan Drug Designation for the Management of Postherpetic Neuralgia 8:44 a.m. Sept. 27, 2013 - BusinessWire